West Virginia Medicaid spending on GLP-1 drugs

How much did West Virginia Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $91.6 million for GLP-1 drugs paid through West Virginia Medicaid in 2025, across at least 94,999 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 53 rows of 149, so these figures are floors.

Pharmacies were reimbursed at least $25.0 million for GLP-1 drugs paid through West Virginia Medicaid in 2026 (quarter 1 only, as posted so far), across at least 25,520 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 10 rows of 41, so these figures are floors.

By year and ingredient

2020at least $6,250,175No data$2,585,181at least $1,107,710at least $568,805SuppressedSuppressedat least $10,511,871
2021at least $14,714,921No dataat least $2,968,131at least $7,803,473at least $109,985at least $22,829Suppressedat least $25,619,339
2022at least $26,979,062at least $16,535at least $2,830,835at least $14,403,603at least $33,632at least $32,149Suppressedat least $44,295,815
2023at least $54,839,119at least $1,229,773at least $3,081,677at least $20,343,390Suppressedat least $8,829Suppressedat least $79,502,788
2024at least $68,029,222$1,884,438at least $1,738,376at least $15,043,201SuppressedSuppressedNo dataat least $86,695,237
2025at least $73,624,792at least $2,534,849at least $723,428at least $14,701,478SuppressedSuppressedNo dataat least $91,584,548
2026 (Q1)at least $19,789,626$970,592at least $194,844$4,066,509No dataSuppressedNo dataat least $25,021,572

By product, 2025

Ozempicat least $73,422,261at least 75,6567 of 20
Rybelsusat least $99,341at least 1015 of 12
Wegovyat least $103,190at least 7815 of 20
Mounjaro$2,293,1102,0280 of 24
Zepboundat least $241,739at least 2299 of 16
Liraglutide (generic name listing)at least $246,869at least 5577 of 23
SaxendaSuppressedSuppressed3 of 3
Victoza$476,5597810 of 8
Trulicityat least $14,701,478at least 15,5694 of 20
BydureonSuppressedSuppressed1 of 1
SoliquaSuppressedSuppressed2 of 2

By quarter, 2025

Q1 2025at least $19,517,003at least 20,43113 of 32
Q2 2025at least $23,461,376at least 24,27514 of 39
Q3 2025at least $25,563,943at least 26,44314 of 38
Q4 2025at least $23,042,226at least 23,85012 of 40

By quarter, 2026 (posted so far)

Q1 2026at least $25,021,572at least 25,52010 of 41

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.